NYSE · Healthcare · Drug Manufacturers—General
Johnson & Johnson (JNJ)
As of Sep 25, 4:00 PM ET, Johnson & Johnson (JNJ) last traded at $271.22, up 0.20% on the day. Its TickerHum research score is 65/100 (above average). It reported revenue of $97.93B for the twelve months ending 2026-06-28, up 8.1% year over year, with a 22.2% operating margin.
Ratings
- Valuation: 60/100 — Strongest input: price / sales (ttm) 6.7x. Weakest: free-cash-flow yield 3.4 %.
- Growth: 33/100 — Strongest input: revenue growth (ttm, yoy) +8.1 %. Weakest: diluted eps growth (ttm, yoy) -7.7 %.
- Profitability: 83/100 — Strongest input: gross margin 67.9 %. Weakest: operating margin 22.2 %.
- Financial health: 45/100 — Strongest input: long-term debt / equity 0.44. Weakest: current ratio 1.09.
- Momentum: 74/100 — Strongest input: 1-year return +50.9 %. Weakest: 3-month return +6.5 %.
- Attention: 51/100 — Strongest input: headlines in the last 7 days 24. Weakest: volume vs 3-month average 0.6x.
- Risk: 92/100 — Strongest input: annualised volatility (1y) 18.9 %. Weakest: max drawdown (1y) -11.0 %.
- Data confidence: 92/100 — Strongest input: inputs available 100 %. Weakest: quote age (hours) 45 h.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $97.93B | TTM ending 2026-06-28 · 10-Q |
| Revenue growth | 8.1% | TTM ending 2026-06-28 · 10-Q |
| Net income | $21.04B | TTM ending 2026-06-28 · 10-Q |
| Diluted EPS | $8.62 | TTM ending 2026-06-28 · 10-Q |
| Gross margin | 67.9% | TTM ending 2026-06-28 · 10-Q |
| Operating margin | 22.2% | TTM ending 2015-03-29 · 10-Q |
| Net margin | 21.5% | TTM ending 2026-06-28 · 10-Q |
| Free cash flow | $22.24B | TTM ending 2026-06-28 · 10-Q |
| Cash | $20.42B | as of 2026-06-28 · 10-Q |
| Long-term debt | $37.34B | as of 2026-06-28 · 10-Q |
| Debt / equity | 0.44 | as of 2026-06-28 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000200406).
Compare Johnson & Johnson with its closest competitors
- Johnson & Johnson vs AbbVie (JNJ vs ABBV) — Same industry (Drug Manufacturers—General); market cap 0.71x
- Johnson & Johnson vs Eli Lilly and (JNJ vs LLY) — Same industry (Drug Manufacturers—General); market cap 1.7x
- Johnson & Johnson vs Merck & Co. (JNJ vs MRK) — Same industry (Drug Manufacturers—General); market cap 0.56x
- Johnson & Johnson vs Amgen (JNJ vs AMGN) — Same industry (Drug Manufacturers—General); market cap 0.34x
- Johnson & Johnson vs Gilead Sciences (JNJ vs GILD) — Same industry (Drug Manufacturers—General); market cap 0.29x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.